ADD3

Across TCGA pan-cancer cohorts, ADD3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADD3 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADD3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ADD3 expression acts as an unfavorable survival marker, although some lineages such as PDAC and COAD show a favorable association.

PDAC, COAD, and LUAD are the cancer types where ADD3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.671	0.405	<.001	115	view →
COAD	DFS	Median	II,III,IV	1.000	0.912	.013	42	view →
LUAD	DFS	Quartile	All	0.800	0.414	<.001	21	view →
CCRCC	OS	Quartile	II,III,IV	0.977	0.104	.036	6	view →
HNSC	DFS	Quartile	All	0.517	0.770	.019	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADD3–PDAC (OS)

Open the PDAC breakdown →